Linked e-resources
Details
Table of Contents
Preface; Contents; Part I: From Ovulation to Assisted Reproduction: New Insight and Strategies; 1: Luteal-Phase Stimulation; 1.1 Introduction; 1.2 Physiological Bases; 1.3 Applications of Luteal-Phase Stimulation; 1.3.1 Luteal-Phase Stimulation for Fertility Preservation; 1.3.2 Luteal-Phase Stimulation in an Egg-Donation Programme; 1.3.3 Luteal-Phase Stimulation in IVF Patients; 1.3.4 Luteal-Phase Stimulation in the Low Responder; 1.4 Discussion; References; 2: Management of Luteal Phase in IVF Cycles; 2.1 Introduction; 2.2 Physiopathology of the Luteal Phase in Stimulated Cycles
2.3 Luteal Phase Support After HCG Triggering2.4 Luteal Phase Support After GnRH Agonist Triggering; 2.5 GnRH Cotreatment in the Luteal Phase; 2.6 Cessation of Luteal Support; References; 3: Genomics and Ovarian Response; 3.1 Introduction; 3.2 Follicular Development and Angiogenesis; 3.3 FSH, LH, and Their Receptors; 3.4 Oocyte Development and Quality; 3.5 Follicular Development and Signaling Pathways; 3.6 Progesterone and Its Receptors; 3.7 Endometrial Development and Receptivity; Conclusions; References; 4: Management of Poor Responders; 4.1 Introduction
4.2 Ovarian Reserve Markers4.2.1 Basal FSH; 4.2.2 Anti-Müllerian Hormone; 4.2.3 Antral Follicle Count (AFC); 4.2.4 History of Risk Factors for Low Reserve; 4.3 Therapeutic Options in Low Responders; 4.3.1 Ovarian Androgenisation; 4.3.2 Growth Hormone; 4.3.3 Oocyte Accumulation; Conclusions; References; 5: Gene Expression in Cumulus Cells and Oocyte Quality; 5.1 Introduction; 5.2 Gene Modulation of Granulosa Cells During Folliculogenesis; 5.3 Granulosa Cells Transcriptome Analysis; 5.4 Granulosa Cells Transcriptome Analysis: The Ovarian Stimulation Effect
5.5 Granulosa Cells Transcriptome Analysis: Polycystic Ovarian Syndrome Conclusions; References; Part II: AMH, Ovarian Ageing and Premature Ovarian Insufficency Fertility; 6: Biomarkers of Ovarian Ageing; 6.1 Introduction; 6.2 Biomarkers; 6.2.1 Antral Follicle Count (AFC); 6.2.2 Follicle-Stimulating Hormone (FSH); 6.2.3 Estradiol (E2); 6.2.4 Luteinizing Hormone (LH); 6.2.5 Inhibin-B; 6.2.6 Anti-Müllerian Hormone (AMH); Conclusions; References; 7: Premature Ovarian Insufficiency: Advances in Management Through a Global Registry; 7.1 Predictive Tests
7.2 Counselling and Emotional Support7.3 Hormone Replacement Therapy; 7.4 Fertility; 7.5 POI Registry; 7.5.1 Principles of POI Registry; 7.5.2 Potential Benefits of POI Registry; 7.5.3 POI Registry Progress in 2015; Conclusion; References; 8: The Long-Term Risks of Premature Ovarian Insufficiency; References; Part III: Gynecological Neuroendocrinology; 9: Pharmacological and Integrative Treatment of Stress-Induced Hypothalamic Amenorrhea; 9.1 Introduction; 9.2 Neuroendocrine Mechanisms of Stress-Induced Hypogonadism; 9.3 Neuroendocrine Mechanism of Hypothalamic Amenorrhea
2.3 Luteal Phase Support After HCG Triggering2.4 Luteal Phase Support After GnRH Agonist Triggering; 2.5 GnRH Cotreatment in the Luteal Phase; 2.6 Cessation of Luteal Support; References; 3: Genomics and Ovarian Response; 3.1 Introduction; 3.2 Follicular Development and Angiogenesis; 3.3 FSH, LH, and Their Receptors; 3.4 Oocyte Development and Quality; 3.5 Follicular Development and Signaling Pathways; 3.6 Progesterone and Its Receptors; 3.7 Endometrial Development and Receptivity; Conclusions; References; 4: Management of Poor Responders; 4.1 Introduction
4.2 Ovarian Reserve Markers4.2.1 Basal FSH; 4.2.2 Anti-Müllerian Hormone; 4.2.3 Antral Follicle Count (AFC); 4.2.4 History of Risk Factors for Low Reserve; 4.3 Therapeutic Options in Low Responders; 4.3.1 Ovarian Androgenisation; 4.3.2 Growth Hormone; 4.3.3 Oocyte Accumulation; Conclusions; References; 5: Gene Expression in Cumulus Cells and Oocyte Quality; 5.1 Introduction; 5.2 Gene Modulation of Granulosa Cells During Folliculogenesis; 5.3 Granulosa Cells Transcriptome Analysis; 5.4 Granulosa Cells Transcriptome Analysis: The Ovarian Stimulation Effect
5.5 Granulosa Cells Transcriptome Analysis: Polycystic Ovarian Syndrome Conclusions; References; Part II: AMH, Ovarian Ageing and Premature Ovarian Insufficency Fertility; 6: Biomarkers of Ovarian Ageing; 6.1 Introduction; 6.2 Biomarkers; 6.2.1 Antral Follicle Count (AFC); 6.2.2 Follicle-Stimulating Hormone (FSH); 6.2.3 Estradiol (E2); 6.2.4 Luteinizing Hormone (LH); 6.2.5 Inhibin-B; 6.2.6 Anti-Müllerian Hormone (AMH); Conclusions; References; 7: Premature Ovarian Insufficiency: Advances in Management Through a Global Registry; 7.1 Predictive Tests
7.2 Counselling and Emotional Support7.3 Hormone Replacement Therapy; 7.4 Fertility; 7.5 POI Registry; 7.5.1 Principles of POI Registry; 7.5.2 Potential Benefits of POI Registry; 7.5.3 POI Registry Progress in 2015; Conclusion; References; 8: The Long-Term Risks of Premature Ovarian Insufficiency; References; Part III: Gynecological Neuroendocrinology; 9: Pharmacological and Integrative Treatment of Stress-Induced Hypothalamic Amenorrhea; 9.1 Introduction; 9.2 Neuroendocrine Mechanisms of Stress-Induced Hypogonadism; 9.3 Neuroendocrine Mechanism of Hypothalamic Amenorrhea